相关实验视频
Updated: Mar 11, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.6K
目前的治疗算法:扩散大B细胞淋巴瘤
Stephen M Ansell1, Grzegorz S Nowakowski2
1Division of Hematology, Mayo Clinic, Rochester, MN, USA. Ansell.stephen@mayo.edu.
Blood cancer journal
|March 10, 2026
概括
扩散性大B细胞淋巴瘤 (DLBCL) 治疗的目标是治愈,大约三分之二的患者实现长期存活. 进展包括向疗法和细胞治疗,但研究继续改善复发性或耐火性DLBCL的结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的B细胞癌症,也是最常见的淋巴瘤亚型.
- 目前的治疗方法提供治疗意图,大约66%的患者实现了持久的长期存活.
- 治疗策略是根据风险调整的,考虑疾病阶段,预后因素和分子亚型.
研究的目的:
- 概述扩散型大B细胞淋巴瘤 (DLBCL) 的当前管理策略.
- 讨论基于疾病特征和患者子组的治疗方法.
- 突出正在进行的DLBCL新疗法的研究.
主要方法:
- 对DLBCL当前治疗指南和临床实践的审查.
- 描述一线,二线和息治疗模式.
- 在临床试验中提到新兴的细胞和双特异性疗法.
主要成果:
- 以人环素为基础的化学疗法与rituximab是标准的初始疗法.
- 特定的亚型 (例如,激活B细胞) 和遗传重组 (Myc,BCL-2) 指导治疗的强化.
- 化学抗原受体 (CAR) T细胞疗法和自主干细胞移植的救援化疗是疾病复发的关键.
结论:
- 尽管采取了适应风险的策略,但至少有三分之一的DLBCL患者复发.
- 息选择包括双特异性抗体和抗体与药物合物,用于耐火病例.
- 包括细胞和双特异性药物在内的研究疗法正在被整合到前线治疗中,以改善DLBCL的结果.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K